Loading...
XSHG600750
Market cap1.85bUSD
Dec 26, Last price  
21.55CNY
1D
-2.00%
1Q
-2.40%
Jan 2017
46.84%
Name

Jiang Zhong Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600750 chart
P/E
19.03
P/S
3.07
EPS
1.13
Div Yield, %
5.94%
Shrs. gr., 5y
0.17%
Rev. gr., 5y
20.12%
Revenues
4.39b
+15.18%
834,475,194979,471,3431,181,073,4551,168,589,3041,457,643,3111,890,024,3312,563,606,1992,647,303,9293,191,844,6942,777,861,3432,834,124,3392,597,351,4341,561,863,0811,746,642,5281,755,229,0222,449,404,4422,441,451,7892,873,974,4623,811,641,5104,390,101,978
Net income
708m
+18.40%
43,115,10153,629,43976,323,26496,599,416130,618,543201,095,148261,203,025227,818,447225,336,056172,255,405264,847,938367,012,144379,763,770417,796,582470,248,224463,596,527473,739,388505,687,248598,241,179708,291,520
CFO
1.04b
+1.96%
26,281,353198,445,96755,242,615153,631,577268,873,134378,316,022222,292,622168,295,685226,380,995111,918,811356,804,768510,778,275698,045,543124,928,619486,245,960641,177,784752,501,253917,037,6601,015,989,4161,035,899,563
Dividend
Oct 10, 20240.5 CNY/sh
Earnings
May 16, 2025

Profile

Jiang Zhong Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of traditional Chinese medicine and health foods. The company offers OTC class products for gastrointestinal digestion, upper respiratory tract, and tonics; protein nutrition, tonics, health regimen, probiotics, daily protection, beauty, bone health, and plant liver protection health products; and prescription products. It sells its products under the Jiangzhong and Jianweixiaoshi brands. Jiang Zhong Pharmaceutical Co.,Ltd is based in Nanchang, China.
URL
https://www.jzjt.com/
IPO date
Sep 23, 1996
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,390,102
15.18%
3,811,642
32.63%
2,873,974
17.72%
Cost of revenue
3,042,676
2,961,586
2,186,339
Unusual Expense (Income)
NOPBT
1,347,426
850,055
687,635
NOPBT Margin
30.69%
22.30%
23.93%
Operating Taxes
130,470
106,795
92,190
Tax Rate
9.68%
12.56%
13.41%
NOPAT
1,216,956
743,260
595,445
Net income
708,292
18.40%
598,241
18.30%
505,687
6.74%
Dividends
(800,503)
(724,019)
(308,701)
Dividend yield
6.06%
8.03%
3.38%
Proceeds from repurchase of equity
(1,120)
802
BB yield
0.01%
-0.01%
Debt
Debt current
1,989
1,702
Long-term debt
2,095
2,352
5,581
Deferred revenue
67,845
73,045
Other long-term liabilities
48,938
1
1
Net debt
(1,493,716)
(2,739,824)
(2,766,489)
Cash flow
Cash from operating activities
1,035,900
1,015,989
917,038
CAPEX
(208,879)
Cash from investing activities
(182,431)
79,425
Cash from financing activities
(817,048)
FCF
1,139,518
443,642
989,615
Balance
Cash
1,382,944
2,744,164
2,773,772
Long term investments
112,868
Excess cash
1,276,306
2,553,582
2,630,074
Stockholders' equity
4,143,646
4,188,230
4,282,524
Invested Capital
3,248,785
1,938,883
1,981,042
ROIC
46.92%
37.92%
27.79%
ROCE
29.66%
18.83%
14.84%
EV
Common stock shares outstanding
632,403
623,700
632,109
Price
20.88
44.50%
14.45
0.00%
14.45
36.19%
Market cap
13,204,578
46.51%
9,012,464
-1.33%
9,133,976
36.65%
EV
12,354,448
6,877,052
6,946,942
EBITDA
1,468,861
972,000
803,076
EV/EBITDA
8.41
7.08
8.65
Interest
7,834
4,380
3,462
Interest/NOPBT
0.58%
0.52%
0.50%